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Background: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications,
early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying
treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based
guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS
or HbS/β0 thalassemia) aged as early as 9 months. However, the uptake remains suboptimal, likely because caregivers lack
information about hydroxyurea and have concerns about its safety and potential long-term side effects. Moreover, clinicians do
not routinely receive training or tools, especially those that provide medical evidence and consider caregivers’ preferences and
values, to facilitate a shared discussion with caregivers.
Objective: The aim of this study is to understand how best to help parents of young children with sickle cell disease and their
clinicians have a shared discussion about hydroxyurea (one that considers medical evidence and parent values and preferences).
Methods: We designed our study to compare the effectiveness of two methods for disseminating hydroxyurea guidelines to
facilitate SDM: a clinician pocket guide (ie, usual care) and a clinician hydroxyurea SDM toolkit (H-SDM toolkit). Our primary
outcomes are caregiver reports of decisional uncertainty and knowledge of hydroxyurea. The study also assesses the number of
children (aged 0-5 years) who were offered and prescribed hydroxyurea and the resultant health outcomes.
Results: The Ethics Committee of the Cincinnati Children’s Hospital Medical Center approved this study in November 2017.
As of February 2021, we have enrolled 120 caregiver participants.
Conclusions: The long-term objective of this study is to improve the quality of care for children with SCA. Using multicomponent
dissemination methods developed in partnership with key stakeholders and designed to address barriers to high-quality care,
caregivers of patients with SCA can make informed and shared decisions about their health.
Trial Registration: ClinicalTrials.gov NCT03442114; https://clinicaltrials.gov/ct2/show/NCT03442114
International Registered Report Identifier (IRRID): DERR1-10.2196/27650
(JMIR Res Protoc 2021;10(5):e27650) doi: 10.2196/27650
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Introduction
Background
Sickle cell anemia (SCA) is a genetic blood disorder that affects
approximately 100,000 individuals in the United States [1]. It
is the most common disorder identified by newborn screening,
with approximately 1 in 2000 babies born with SCA in the
United States each year [2]. SCA is a chronic disease that is
associated with significant morbidity and early mortality [3].
Until 2017, hydroxyurea was the only approved
disease-modifying treatment for individuals with SCA, and it
has remained the only treatment option for children younger
than 5 years [4]. Hydroxyurea has many beneficial effects,
including reduced pain and acute chest syndrome episodes,
reduced hospital admissions, and less need for blood
transfusions, among patients with SCA [5,6]. In 2014, the
National Heart, Lung, and Blood Institute (NHLBI) published
guidelines that recommended clinicians offer hydroxyurea to
children with SCA (HbSS and HbS/β0 thalassemia), beginning
as early as 9 months of age [7]. Previously, medical providers
only offered hydroxyurea to children with SCA with persistent
pain or other severe SCA-related complications. Despite these
guidelines, hydroxyurea uptake remains low in young children
with SCA [8]. Barriers to taking hydroxyurea include a lack of
caregiver knowledge about hydroxyurea, providers’ hesitancy
to prescribe hydroxyurea, and concerns about poor adherence
to the treatment [9].
NHLBI guidelines encourage using shared decision making
(SDM) when providers offer hydroxyurea, which involves a
collaborative process wherein clinicians, patients, and families
work together to reach a mutual agreement about the course of
treatment [7,10]. However, the only widely distributed tool to
assist providers in implementing the NHLBI guidelines for
hydroxyurea is a clinician pocket guide developed by the
American Society of Hematology (ASH) [8]. The pocket guide
was a critical first step, but it only targeted clinician motivation.
Pocket guides do not provide training to build clinician
self-efficacy in prescribing medications, feedback to reinforce
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behavior change, or decision support tools to help clinicians
engage and support caregivers in SDM.
Objectives
We developed the hydroxyurea SDM toolkit (H-SDM toolkit),
which is a caregiver-centered, technology-enhanced decision
support tool. We designed the H-SDM toolkit to strengthen
SDM, reduce caregiver uncertainty, allay potential fears,
increase the offering of hydroxyurea, and ultimately improve
hydroxyurea uptake [10,11]. In this paper, we present a protocol
for a multisite randomized controlled trial (RCT; ENGAGE
HU). The objective of the ENGAGE HU trial is to determine
whether the use of the H-SDM toolkit is more effective than
the ASH clinician pocket guide (ie, usual care) as a
dissemination method. This study aims to improve the quality
of the available evidence so that caregivers and providers have




The Reach, Effectiveness, Adoption, Implementation, and
Maintenance (RE-AIM) model provides a framework for
evaluating dissemination methods that can improve the
sustainable adoption and implementation of effective,
generalizable, and evidence-based interventions by attending
to 5 factors: (1) Reach: does the intervention reach the intended
population?; (2) Efficacy or effectiveness: does the intervention
impact the essential outcomes?; (3) Adoption: is the intervention
supported by staff, settings, or institutions?; (4) Implementation:
is the intervention delivered consistently?; and (5) Maintenance:
what is in place to ensure that the intervention continues over
time? [12]. We developed our study plan using RE-AIM because
this framework improves the quality, speed, and impact of
dissemination methods [13].
Specific Aims
The H-SDM toolkit engages both caregivers and clinicians and
targets (1) clinician motivation and self-efficacy and (2)
caregiver readiness. Therefore, we propose that it will lead to
change in caregiver’s and clinician’s behavior, which will
increase SDM about hydroxyurea between caregivers and
clinicians as well as improve decisional outcomes (ie, decisional
uncertainty, hydroxyurea knowledge, and satisfaction with the
decision-making process; Figure 1) [10]. If caregivers of
children with SCA feel more confident and knowledgeable
about hydroxyurea and more involved in the decision-making
process, then they may be more likely to initiate hydroxyurea
and subsequently ensure that their child adheres to the
medication. Thus, the primary aims of the ENGAGE HU study
are as follows:
• Aim 1: To determine whether the H-SDM toolkit is a more
effective dissemination method than the ASH clinician
pocket guide (ie, usual care) by assessing the following:
• Caregiver report of decisional uncertainty for
hydroxyurea
• Caregiver report of experiencing SDM while talking
with their child’s clinician about hydroxyurea.
• Hypothesis 1: The H-SDM toolkit dissemination method
will result in greater perceptions of SDM and less
uncertainty among caregivers of children with SCA than
the ASH clinician pocket guide (ie, usual care).
• Aim 2: To determine whether the H-SDM toolkit is a more
effective dissemination method than the ASH clinician
pocket guide (ie, usual care) by assessing the following:
• Caregiver knowledge of hydroxyurea
• Whether the children are offered hydroxyurea
• Number of children with an active hydroxyurea
prescription
• Child health outcomes: pain, cognitive function,
SCA-related quality of life, and health care utilization.
• Hypothesis 2: The H-SDM toolkit dissemination method
will result in greater improvements in caregiver knowledge
about hydroxyurea, more children being offered and
receiving hydroxyurea, and better health outcomes than the
ASH clinician pocket guide (usual care).
Figure 1. Engaging parents of children with sickle cell disease and their providers in shared decision making for hydroxyurea (ENGAGE HU) conceptual
model. H-SDM: hydroxyurea shared decision making; SDM: shared decision making.
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Overview of Study Design
ENGAGE HU is an adapted stepped-wedge, stratified,
multicenter RCT [14] with the H-SDM toolkit as the intervention
and the ASH clinician pocket guide as the active comparator.
We selected sites in the United States with sickle cell clinics
that work with patient populations from urban, suburban, and
rural communities. Each clinic begins to enroll patients using
the ASH clinician pocket guide as the dissemination method.
Each site then crosses over to using the H-SDM toolkit (Figure
2). Clinician training for the H-SDM toolkit begins during the
last month of each usual care period. A stepped-wedge design
with sequential assignment was chosen to ensure that all sites
received the intervention and could step in at different
timepoints. All sites will complete the usual care condition first,
as clinicians would not be able to unlearn skills gained from
the H-SDM toolkit. Each site enrolls approximately 4-5
participants per period. Enrollment ends 44 months after the
study initiation (Figure 2).
Figure 2. Study timeline. H-SDM: hydroxyurea shared decision making; IRB: institutional review board.
Randomization
We chose an adapted stepped-wedge randomized trial (clinic
is the unit of randomization) with sites not previously exposed
to the H-SDM toolkit. This design maximizes our confidence
that differences in outcomes between the groups occur due to
the dissemination method and not baseline discrepancies among
participant groups, confounding, or chance. We randomize at
the site level to reduce the risk of contamination and because
the NHLBI guidelines require clinics to make system-level
changes to deliver high-quality care. The order in which the
sites crossover is random (Figure 2). The randomization
minimizes differences among large (>501 patients), medium
(270-500 patients), and small (<270 patients) sites.
Patient Involvement
Patients with SCA and their caregivers provided input at several
stages of the trial, including development, design, feasibility,
and trial conduct. They also assisted with the toolkit
components, choice of outcome measures, and recruitment
methods. They helped us carefully assess the trial burden on
caregivers of patients with SCA. Stakeholders will be coauthors
of peer-reviewed publications, and the study results in a format
suitable for a nonspecialist audience will be sent to the patients
and caregivers.
Eligibility and Consent
Eligibility criteria for the caregiver participants in the ENGAGE
HU study include the following: their child has a diagnosis of
SCA and receives care at the recruitment site; their child is aged
0-5 years; their child is eligible for hydroxyurea according to
NHLBI guidelines (HbSS and HbS/β0 thalassemia); they can
participate in both study visits; and they can read, understand,
and speak English fluently. Exclusion criteria include their child
has an active hydroxyurea prescription filled in the past 3
months; they have previously made a decision about whether
to initiate hydroxyurea (after November 2019, we changed this
criterion to include whether the research team had approached
the caregiver reinitiation of hydroxyurea within the past 3
months); any diagnoses or conditions that, in the opinion of the
site investigator or hematologist, would prevent the patient from
being a suitable candidate for the study; and their child is a
sibling of a participant actively or previously enrolled in the
study.
The Cincinnati Children’s Hospital Medical Center (CCHMC)
is the co-ordinating center (CC) for this multisite trial
(Multimedia Appendix 1 [14-39]). The CCHMC oversees the
study conduct, regulatory and institutional review board (IRB)
administration, and compliance. The protocol for ENGAGE
HU includes an IRB-approved waiver of the documentation of
consent for clinicians participating in the trial. The trial also
has an IRB-approved waiver of consent that permits clinical
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sites to generate a list of eligible patients. Caregivers participate
in the informed consent process and are required to provide
written or electronic consent.
Recruitment and Retention
The ENGAGE HU trial consecutively enrolls caregivers of
patients with SCA across the United States. Caregivers are
identified as potentially eligible for hydroxyurea by provider
referral or electronic health record review. A member of the
site research team approaches the child’s hematology provider
to obtain approval before contacting the potential caregiver
participant. Caregivers of patients deemed eligible will receive
an invitation via regular mail or phone or may be approached
during a clinic visit, with research coordinators at each site
screening participants and completing the informed consent
process.
Evidence-based strategies for optimizing participation and
retention include scheduling visits at times convenient for the
family, reminder phone calls, allowing participants to complete
questionnaires on the internet, scheduling phone or video
problem-solving sessions at a convenient time, and check-in
calls during the COVID-19 pandemic. In addition, the
importance of the follow-up visit is reviewed with each family
at baseline to engage them as partners in the research process.
We also seek to aid sites in developing solutions to reach
nonresponders during weekly study meetings. To improve
retention, we collect multiple forms of contact information from
multiple contacts (eg, family members and friends) to stay in
close contact with families. In addition, we use a graduated
incentive system for visits to reduce attrition. A Stakeholder
Advisory Council, whose members include the caregivers of
patients with SCA, reviews and provides ongoing feedback on
the recruitment and retention plan.
Hydroxyurea Dissemination Methods
H-SDM Toolkit
Guided by the social cognitive theory, and considering
preidentified barriers [40], the team designed the H-SDM toolkit
to increase the likelihood that caregivers and health care
providers would engage with one another to make a joint
decision about hydroxyurea. The social cognitive theory posits
that behavior change occurs when an individual is motivated,
feels confident in his or her ability to perform the new behavior
(self-efficacy), and observes that the behavior is successfully
performed and reinforced by others (observational learning and
reinforcement). The development of the H-SDM toolkit is
described in detail elsewhere [11]. Briefly, our research team
collaborated with clinicians, educators, community-based
organizations, and patients with SCA and their caregivers to
identify barriers related to decision making regarding
hydroxyurea. We designed the H-SDM toolkit with core and
optional components tailored to individuals’ needs while also
being broadly applicable (Table 1).
Clinicians participate in guided practice using the visit decision
aids in an immersive virtual reality environment [41] (Figure
3). The virtual reality simulation was adapted from a general
pediatric practice protocol to train clinicians to discuss the
influenza vaccine with racial and ethnic minority families [42].
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Table 1. Hydroxyurea shared decision-making toolkit components.
OptionalCoreProcessComponentMaterials
N/Ab✓aClinicians receive virtual reality training to increase their self-effi-
cacy in describing hydroxyurea risks, benefits, and other treatments;
eliciting caregiver preferences; assessing decision readiness; and
moving caregivers toward a decision
Guided practiceVirtual reality simulation
✓N/ATo increase caregiver motivation to make a decision by providing
information about hydroxyurea as a treatment option
Decision aidPrevisit brochure
N/A✓To increase caregiver self-efficacy by providing them with the in-
formation needed to evaluate the benefits and risks of hydroxyurea
and other treatment options
Decision aidIn-visit issue card
N/A✓Includes links to reputable resources; caregivers can take notes
and take this resource home to share with other caregivers involved
in decision making
Decision aidAfter-visit booklet
✓N/AFour videos (3 mothers and 1 father)—caregivers telling their
story about how they made a decision about hydroxyurea
Decision aidParent video narratives





✓N/ASecure SharePoint site with tools to identify eligible patients who
were missed or not approached
Identifying eligible
patients
Care gap report template
✓N/ASecure SharePoint site with a SCAc data collection form for




N/A✓Sites are provided with quality improvement tools that help inte-
grate guidelines into their care delivery system. Process maps vi-
sually describe the flow of work or ideas
ImplementationProcess map template
✓N/AFailure mode effect analysis templates assist teams in determining
how their clinic process needs to change to incorporate the NHLBId
guidelines into routine care
ImplementationFailure mode effect analysis
template
✓N/APlan-do-study-act templates assist teams in determining how their
clinic process needs to change to incorporate the NHLBI guidelines
into routine care
ImplementationPlan-do-study-act template
✓N/ASite teams complete key driver diagrams, which are a visual display
of a team’s theory of what “drives” or contributes to the study aims
ImplementationKey driver diagram template
N/A✓Teams are invited to weekly calls and booster sessions to review




N/A✓For use in shared decision makingMonitoringRun chart template 1
N/A✓To track eligible patients who have been offered hydroxyureaMonitoringRun chart template 2
✓N/ATo track hydroxyurea prescriptionsMonitoringRun chart template 3
✓N/ATable of dates and laboratory values with a way for clinicians to
indicate if a value is in range or moving in the right direction
MonitoringHydroxyurea navigator
monitoring tool (dose, labs,
and adherence)
aCheck marks indicate whether a component of the toolkit is core or optional.
bN/A: not applicable.
cSCA: sickle cell anemia.
dNHLBI: The National Heart, Lung, and Blood Institute.
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Figure 3. The clinical environment viewed through the virtual reality headset.
Usual Care
The ASH clinician pocket guide contains information that may
motivate clinicians to use an SDM approach (eg, the NHLBI
guidelines). The guide also includes information that may
increase clinician confidence in describing hydroxyurea risks,
benefits, and other treatments to caregivers. All sites receive
printed copies of the guide, a link to download copies, and a
link to the app to distribute to their clinicians. Site clinicians
also view a live or recorded didactic presentation that reviews
the NHLBI guidelines for hydroxyurea. Sites then develop or
update their site-specific care guidelines for hydroxyurea and
create a plan for implementation.
Procedures
Once the research team obtains consent from interested
caregivers, they can complete baseline assessments at that time
or a more convenient date. If caregivers prefer or cannot
complete measures in person, then they can complete them on
internet using Research Electronic Data Capture (REDCap)
[43]. If a caregiver does not complete baseline assessments
within 30 days of consent, then the caregiver may be rescreened,
reconsented, and asked to complete baseline assessments one
more time. At baseline, caregiver participants discuss initiating
hydroxyurea with providers, and measures may be completed
over 1-2 visits with 3 baseline visit types: (1) Full baseline:
caregiver completes all baseline measures during one visit, (2)
Baseline part 1: caregiver participants complete baseline
measures not dependent upon the hydroxyurea discussion, and
(3) Baseline part 2: caregiver participants complete baseline
measures relevant to hydroxyurea discussion (Table 1).
The follow-up visit occurs between 3 and 7 months after
baseline, and caregiver participants can complete measures
during a clinic visit or on the internet. After both the baseline
and follow-up visits, clinicians or research staff document
whether they offered or prescribed hydroxyurea, whether they
used Usual Care or H-SDM toolkit, patient’s health care
utilization, and hematology lab values (Figure 4). Study sites
complete a follow-up survey to assess whether and how their
site is continuing to implement guidelines and whether they are
offering hydroxyurea 3 months after recruitment ends. Caregiver
participants are compensated US $40 for completion of baseline
measures, US $20 for partial completion, US $20 for
hydroxyurea discussion, and US $40 for completing all
follow-up measures. We also compensate caregiver participants
US $5 each time they refilled hydroxyurea between baseline
and follow-up time points, verified by electronic medical record
review.
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Figure 4. Study flowchart. H-SDM: hydroxyurea shared decision making; SCD: Sickle Cell Disease.
Primary Outcomes
The decisional conflict scale (DCS) is a 16-item measure that
assesses decisional uncertainty [15]. Items are rated on a 4-point
Likert scale of 0=strongly agree to 4=strongly disagree. To
calculate the total score, the 16 items are summed, divided by
16, and multiplied by 25. The scores range from 0 to 100. The
dyadic OPTION (observing patient involvement) scale is a
measure of the caregiver perception of clinician behaviors
involved in SDM [16]. Parents respond to the following item:
“My doctor and I made the decision together.” The scores range
from 0 to 100 (Table 2).
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Table 2. Primary and secondary outcome measures and covariates and fidelity assessments completed at baseline and follow-up visits in the engaging
caregivers and providers of children with sickle cell anemia in shared decision making for hydroxyurea trial.
Follow-upBaselineBrief descriptionMeasureConstruct
Primary outcomes
N/Ab✓aMeasures uncertainty experienced when feeling uninformed
about options, unclear about personal values, or unsupported










tion of shared decision
making
Secondary outcomes
✓✓Three items adapted from the empirical research related to





tion with decision making
✓✓Hydroxyurea knowledge survey (8 items): developed based
on the existing literature, the Ottawa Knowledge User
8-item survey–effectivenessCaregiver-reported hydrox-
yurea knowledge
Manual, and it was used by caregiver and clinician stakehold-
ers in our pilot work
✓✓Measures several domains of health-related quality of life
including pain impact, fatigue, pain management, emotions,






✓✓Reliable, accurate developmental and social emotional
screener for children aged between 2 and 60 months
Ages and stages question-
naire [45]–effectiveness
Caregiver report of neu-
rocognitive functioning
✓N/AA 9-item survey that measures adherence problems and the
extent of nonadherence in pediatric populations
Medical adherence measure
subscale [46]–effectiveness
Caregiver report of hydrox-
yurea adherence
✓N/AFor the H-SDM condition, caregiver report of continued use
of decision aids: previsit brochure, postvisit booklet, and
narrative videos, including sharing information with others
H-SDMe follow-up surveyCaregiver report of contin-
ued use of decision aids
✓✓One item reported by the research coordinator. They report




tion for hydroxyurea using the EMRf (prescription in the last
6 months)
✓✓Labs reported by the research coordinator based on the EMR
(past 12 months): HbFg level, which increases when taking
Lab values and pharmacy
refill records–effectiveness
Hydroxyurea adherence
hydroxyurea as prescribed, ANCh, which decreases when
taking hydroxyurea as prescribed, and MCVi, which increas-
es when taking hydroxyurea as prescribed
✓✓1 of 3 responses completed by the research coordinator based
on a review of EMR data: hydroxyurea was not offered, of-
1 item reported by research
coordinator–reach
Hydroxyurea offered
fered, or previously prescribed. If not offered, coordinators
choose a reason why (ie, not eligible because the patient is
on transfusions)
✓✓EMR data on the number of hospitalizations, ill visits, and
emergency room visits in the 6 months before enrollment (if
Hospitalizations, emergency
room visits, and ill visits–ef-
fectiveness
Health care utilization
possible, some participants may be 9 months of age) and the
6 months after enrollment
Covariates
N/A✓10-item survey assessing family demographics including
patient and caregiver age, gender, race and ethnicity, socioe-
Demographics surveyDemographics
conomic status, insurance (public vs private), and caregiver
highest level of education completed
N/A✓Newest vital sign (3 min): tests literacy skills for both num-
bers and words
Newest vital sign [19]Health literacy
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✓✓The CEFIS was designed to be used in ongoing and new
studies where COVID-19 may impact study outcomes. It
conceptualizes the exposure to potentially traumatic aspects
of COVID-19 and assesses the pandemic's impact on the
family
CEFISj [47]Caregiver report of the ef-
fects of COVID-19
✓✓Items from the telemedicine usability questionnaire assess






N/A✓Checklist to assess the toolkit components that were used




N/A✓Observer quantifies clinician behaviors to involve a caregiver
in decision making. A total score is calculated, ranging from




vation of decision making








N/ASurvey to assess the continued implementation of the sites'
guidelines and clinical characteristics to understand barriers
and facilitators to maintain implementation
Follow-up survey–mainte-
nance
Study site report of contin-
ued use of intervention
aThe check mark indicates that participants completed the measure either at baseline, follow-up, or both.
bN/A: not applicable.
cSCD: sickle cell disease.
dPedsQL: Pediatric Quality of Life.
eH-SDM: hydroxyurea shared decision making.
fEMR: emergency medical record.
gHbF: fetal hemoglobin.
hANC: absolute neutrophil count.
iMCV: mean corpuscular volume.
jCEFIS: COVID-19 Exposure and Family Impact Survey.
Secondary Outcomes
A 6-item survey assesses satisfaction with decision making
[17,44], and an 8-item survey assesses hydroxyurea knowledge.
If the Cronbach alpha for items on these scales is acceptable
(≥.70), then we will sum the ratings to obtain a total score;
otherwise, we will analyze items separately. The medical
adherence measure assesses problems associated with
hydroxyurea adherence [46]. Nonadherence and late adherence
are calculated as a continuous variable (0%-100%). The
Pediatric Quality of Life Inventory Sickle Cell Module [18] is
a 43-item scale with 9 dimensions that assesses health-related
quality of life in patients with SCA. Caregivers rated how much
of a problem an issue had been for a child on a 5-point scale of
Never to Almost Always. Responses are reverse scored and
linearly transformed to a 0-100 scale. Total scores are the sum
of the items divided by the number of items answered. The Ages
and Stages Questionnaire [45] is a set of questionnaires in which
caregivers’ complete questions appropriate for their child’s
developmental stage. Each developmental area is scored on a
3-point scale of 0=not yet, 5=sometimes, and 10=yes and then
totaled and compared with area cut-off scores. The H-SDM
toolkit follow-up survey measures caregivers’ continued use of
decision aids (Table 2).
Covariates
Covariate analyses will include data from the caregiver
participant completed Demographics Survey and the Newest
Vital Sign Survey [19]. The Newest Vital Sign Survey contains
10 items that assess health literacy skills using a mix of free
response, yes or no, and Likert scale questions such as “how
confident are you filling out medical forms by yourself?” The
research team reviews the electronic health records to collect
data on hydroxyurea (ie, if offered, if there is active prescription,
adherence) based on lab values in the past 12 months, pharmacy
refill records, and health care utilization.
To understand how the COVID-19 pandemic may impact trial
study outcomes (eg, differential levels of distress), we added 2
additional measures in May 2020. The caregiver participants
complete the COVID-19 Exposure and Family Impact Survey
(CEFIS) [47]. The CEFIS contains following subscales: part 1
(exposure) comprises 25 items (yes or no responses) and part
2 (impact) comprises 12 items with 10 items using a 4-point
scale rating impact on caregiver participant’s and family’s life
and 2 items that use a 10-point distress scale. Part 3 is an
open-ended question, so that participants could expand upon
their experiences. Higher scores denote a more negative impact
or exposure. The caregiver participants also complete the
COVID-19 and telemedicine use survey [48], which contains
24 items rated on a 7-point Likert scale of 1=completely disagree
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to 7=completely agree, with statements such as “telehealth
improves my access to health care services.”
Fidelity Assessments
The site study coordinator completes the intervention fidelity
checklist and assesses whether the clinician used the treatment
materials outlined in the protocol. The number of fidelity
assessments that sites complete is determined based on
site-specific expectations for enrollment. We developed the
parent checklist specifically for this study to assess the H-SDM
toolkit components used during the hydroxyurea discussion
with the clinician. To ensure reliability, 2 research coordinators
from the CC site independently code the recorded visits using
the Observer OPTION scale [20]. Clinicians must obtain a score
of 80 or higher. If a score of less than 80 is received, then it
indicates that the clinician or site needs additional training
(1-hour video conference call). Encounters will continue to be
reviewed for fidelity to ensure that the clinician or site is
implementing 80% of the required toolkit components. Finally,
a follow-up survey 1-3 months after enrollment ends assesses
whether sites have continued implementing the H-SDM toolkit
guidelines.
Data Analyses
Data quality will be maintained through double data entry from
site research team members and data quality checks from the
coordinating site coordinator that assesses the conformance,
completeness, and plausibility of electronic REDCap data. The
coordinating site manager will also monitor data quality through
random inspections. Any reliability issues were addressed with
additional training. Discrepancies will be resolved by checking
source data and, if necessary, by returning to patient charts to
correct any inaccuracies.
All analyses will be conducted using Stata version 16 [49].
Before conducting analyses, the primary and secondary outcome
measures’ psychometric properties will be assessed (eg, the
measures’ dimensionality). The characteristics of the sites (eg,
number of clinicians) and participants (eg, health literacy) will
be summarized using descriptive statistics. Additional health
care utilization variables will be analyzed as count variables
and examined in the exploratory analyses.
Primary Outcomes Analyses
To examine differences between usual care and H-SDM toolkit
groups on the DCS scale assessed at a single time point during
the intervention session, a linear mixed-effects regression model
with a robust variance estimator and maximum likelihood
estimation will be used, with observations clustered within site
and alpha set to .05. To examine differences between the usual
care and H-SDM toolkit groups on the OPTION scale, we will
conduct a logistic mixed-effects regression model with a robust
variance estimator, maximum likelihood estimation, and
observations clustered within site with alpha set to .05.
Secondary Outcomes Analyses
Parental knowledge and child health outcomes will be analyzed
using linear mixed-effect regression models, with observations
clustered within the site. To account for possible type I error
inflation due to a large number of secondary outcomes, we will
use the Benjamini-Hochberg procedure [50] to decrease the
false discovery rate, with the overall alpha set to .05. For health
care utilization outcomes, generalized mixed-effect regression
models will be employed, with binary outcomes estimated using
logistic models and count outcomes analyzed with negative
binomial models. The interaction between these demographic
variables and treatment conditions will be included in the
regression models. We will examine the impact of the
COVID-19 pandemic on our trial outcomes by assessing the
interaction between our treatment groups and scores on the
CEFIS in regression models. Observations will be coded as
occurring prepandemic or during pandemic, regardless of
treatment condition assignment.
Subgroup Analyses
We will compare the characteristics of the following subgroups
on outcome variables: (1) caregiver participants who enroll
versus those who decline, (2) dropouts versus completers, (3)
clinicians who adopt the H-SDM toolkit versus those who do
not, (4) sites who adopt the full H-SDM toolkit versus those
that adopt only the core components, (5) sites that continue to
implement guidelines versus those who do not, and (6)
observations collected prepandemic versus during the pandemic.
Process Improvement Analyses
During the H-SDM toolkit period, data are tracked on monthly
run charts, which will be converted into p-charts or control
charts to determine if the process of offering hydroxyurea is
under control (ie, minimal variation in the data) and if there are
any notable changes (ie, factors that change the process). The
upper and lower control limits will be calculated as 3 sigma
from the mean (ie, standard Shewhart chart method) [21]. We
will consider any data point outside the control limit variation
from a special cause.
Fidelity Analyses
We will examine the differences between sites that continue to
implement the intervention components and those who
discontinue the toolkit use.
Statistical Power
We based sample size calculations on the smallest effect sizes
(Cohen d) reported in previous studies using the DCS (effect
sizes range from d=0.4 to 1.2) [22], our primary outcome, and
a stepped-wedge design (eg, Hussey and Hughes approach)
[14,23]. We calculated power analyses using the optimal design
[51] power analysis software. With our planned sample size of
n=87 per group (total sample size N=174) and up to 10%-15%
missing data on our primary outcome, we will have at least 80%
power to detect a standardized effect size difference of d=0.40
between our treatment groups on our primary outcome.
Data and Safety Monitoring
The study oversight will be under the direction of a Data and
Safety Monitoring Board (DSMB) comprising members having
expertise in SDM, hematology, psychology, biostatistics as well
as a parent of a young child with SCA and an adult patient living
with SCA. The DSMB will assess safety and efficacy data (if
applicable), along with study’s progress and data integrity.
These experts will review and evaluate the accumulated data
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for participant safety, adverse events, and study’s conduct and
progress every 6 months. The DSMB will make
recommendations to the appropriate regulatory agencies (IRB
and Patient-Centered Outcomes Research Institute [PCORI])
concerning the continuation, modification, or termination of
the study. Given the study is low risk, there are 2 conference
calls scheduled each year.
Although no adverse events are anticipated, we will ensure that
each site has procedures to refer any parents who become upset
to appropriate resources for follow-up. The principal investigator
(PI), a clinical psychologist with experience in managing
parental distress, will provide study staff and clinician training.
The PI and site PI will be notified if any individual needs
psychological follow-up due to study participation. The IRB at
CCHMC will be notified as soon as the immediate needs of the
participant are addressed. For any severe adverse events (ie,
life-threatening), the study staff will inform the PI within 1
working day. All serious adverse events will be reported to the
IRB within 48 hours of the event.
Results
The ENGAGE HU trial was funded in August 2017, and the
Ethics Committee of CCHMC approved the study (Approval
No. 2017-6612) in November 2017. Patient recruitment started
in July 2018 and will end in November 2021. The study will be
completed in February 2022. As of February 2021, we have
enrolled 120 caregiver participants. We expect to disseminate




The ENGAGE HU trial compares the existing ASH clinician
pocket guide with the H-SDM toolkit, which is a
caregiver-centered, technology-enhanced decision support
toolkit to help clinicians implement SDM for hydroxyurea [11].
We designed the H-SDM toolkit components to increase the
likelihood that caregivers and health care providers would make
a change in their behaviors (ie, engage with one another to make
a decision about hydroxyurea). The H-SDM toolkit targets the
worries, fears, and uncertainty of caregivers regarding
hydroxyurea initiation. Improving hydroxyurea uptake is an
important issue, as it is efficacious for patients with SCA. Given
the broad stakeholder input and our preliminary studies, we
believe that the H-SDM toolkit dissemination method has the
potential to promote SDM and enhance the quality of care
provided to children with SCA [52].
Strengths and Limitations
Several aspects of this trial will enable the rapid adoption of
findings into practice. First, we developed the H-SDM toolkit
with substantial clinician and caregiver input; thus, it contains
components these stakeholders felt were feasible, acceptable,
and essential for improving clinical care. Second, we designed
the H-SDM toolkit with core and optional components so that
it can be tailored to the needs of individual families and be
broadly applicable across many clinical settings. Third, virtual
reality simulation provides guided practice in facilitating an
SDM process. It is also a low-cost clinician training intervention
that will be made accessible on national SCA-focused websites
shared across SCA networks. Virtual reality training can occur
in person or using web-based video conferencing tools (eg,
Zoom or Microsoft Teams) [41], which is especially useful in
the context of the ongoing COVID-19 pandemic. Finally, sites
included in this trial were selected because their patient
populations mirror the larger US SCA population with respect
to economics, geography, and racial and ethnic diversity. This
diversity increases the applicability of our findings to nonstudy
settings and increases the available study pool.
There are some limitations to this study that should be
acknowledged. A critical consideration for the ENGAGE HU
trial is that SCA primarily affects individuals of African and
Hispanic or Latino descent. Although the ENGAGE HU trial
design includes best-practice strategies for recruiting people of
color in research, we may experience recruitment difficulties
because potential participants are mistrustful or have child care
and transportation issues [53]. Furthermore, a successful and
timely completion of clinical trials in the SCA population is
compounded, as it is a rare disease with a smaller pool of
available participants [54]. A potential barrier to intervention
fidelity is the intrinsic difficulty in changing behavior. Given
our goals to alter caregiver-clinician interactions, we address
this barrier through guided practice in the virtual reality
environment and audio recordings of a percentage of
caregiver-clinician hydroxyurea interactions. These interventions
should foster fidelity. Our pilot work indicates that clinicians
currently using the toolkit decision aids find them beneficial
and recommend them to others [11]. Ultimately, we hope that
our study findings will have a substantial impact on improving
health outcomes and decreasing health care costs in pediatric
SCA and other chronic conditions.
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